Neutropenie – wann ist eine GCSF Unterstützung notwendig?

Zusammenfassung

Viele Systemtherapien, die in der Behandlung uroonkologischer Erkrankungen eingesetzt werden, verursachen Störungen der Hämatopoese. Dadurch kann es zum Auftreten einer Neutropenie kommen. Neutropene Patienten sind gegenüber bakteriellen, aber auch anderen Infektionen anfällig, häufig ist Fieber bei diesen Patienten das einzige Symptom. Eine solches neutropenes Fieber bedeutet in aller Regel nicht nur eine lebensbedrohliche Therapiekomplikation mit einer oft deutlichen Einschränkung der Lebensqualität der Patienten, sondern kann durch Therapieverzögerungen oder erforderliche Dosismodifikationen auch die Prognose verschlechtert. Granulozyten-Kolonie-stimulierende Faktoren (GCSF), die eine vermehrte Bildung von neutrophilen Granulozyten stimulieren, können sowohl zur unterstützenden Behandlung bei der febrilen Neutropenie als auch zu deren Prophylaxe eingesetzt werden. Dabei ist die korrekte Indikationsstellung für eine solche GCSF-Unterstützung sowohl vom generellen Risiko einer febrilen Neutropenie, der jeweils eingesetzten Therapie, als auch von individuellen Patientenfaktoren und dem Therapieziel (palliative vs. kurative Therapie) abhängig. Basierend auf den aktuellen Empfehlungen der deutschen sowie internationalen Leitlinien möchte dieser Beitrag einen aktuellen und praxisorientierten Überblick zum Einsatz von GCSF in der Uroonkologie geben.

Abstract

Many systemic treatments used in genitourinary oncology negatively affect haematopoiesis, thus leading to neutropenia. Neutropenic patients are vulnerable to bacterial, and other infections. Often fever is the only symptom in these patients. Neutropenic fever is a major threat for these patients, as it may lead to life-threatening therapy complications that significantly impair the patient’s quality of life, Moreover, it may also worsen the prognosis due to therapy delays or necessary dose modifications. Granulocyte colony stimulating factors (GCSF), which can improve neutrophil granulocyte formation, are used both for supportive treatment in febrile neutropenia and for its prophylaxis. The correct indication for such GCSF support depends on the general risk of febrile neutropenia of the therapy used, as well as on individual patient factors and the treatment intent (palliative vs. curative). Based on the current recommendations both of the German and international guidelines, this article aims to provide an up-to-date and practice-oriented overview of the use of GCSF in uro-oncology.

Schlüsselwörter

Neutropenie - Chemotherapie - Supportivtherapie - Granulozyten-Kolonie-stimulierende Faktoren

Keywords

neutropenia - chemotherapy - supportive care - granulocyte-colony-stimulating factors

Publication History

Received: 22 May 2023

Accepted after revision: 12 July 2023

Article published online:
22 August 2023

• Literatur

• 1 Wang C, Li J. Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials. J Clin Pharm Ther 2021; 46: 571-584 DOI: 10.1111/jcpt.13349.
• 2 Powles T, Rosenberg JE, Sonpavde GP. et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 2021; 384: 1125-1135 DOI: 10.1056/NEJMoa2035807. (PMID: 33577729)
• 3 Tagawa ST, Balar AV, Petrylak DP. et al. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2021; 39: 2474-2485 DOI: 10.1200/JCO.20.03489.
• 4 Zimmer AJ, Freifeld AG. Optimal Management of Neutropenic Fever in Patients With Cancer. J Oncol Pract 2019; 15: 19-24 DOI: 10.1200/JOP.18.00269.
• 5 Klastersky J, Paesmans M, Rubenstein EB. et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2000; 18: 3038-3051 DOI: 10.1200/JCO.2000.18.16.3038. (PMID: 10944139)
• 6 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). Supportive Therapie bei onkologischen PatientInnen – Langversion 1.3, 2020, AWMF Registernummer: 032/054OL. 2020
• 7 Thomas J, Liu F, Link DC. Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor. Curr Opin Hematol 2002; 9: 183-189 DOI: 10.1097/00062752-200205000-00002. (PMID: 11953662)
• 8 (NCCN) NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Hematopoietic Growth Factors – Version 2.2023. 2023
• 9 Klastersky J, de Naurois J, Rolston K. et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Annals of oncology: official journal of the European Society for Medical Oncology /ESMO 2016; 27: v111-v118 DOI: 10.1093/annonc/mdw325. (PMID: 27664247)
• 10 Taplitz RA, Kennedy EB, Bow EJ. et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2018; 36: 1443-1453 DOI: 10.1200/JCO.2017.77.6211. (PMID: 29461916)
• 11 Leonard RC, Mansi JL, Keerie C. et al. A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN. Annals of oncology: official journal of the European Society for Medical Oncology /ESMO 2015; 26: 2437-2441 DOI: 10.1093/annonc/mdv389. (PMID: 26416895)
• 12 Hartmann LC, Tschetter LK, Habermann TM. et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997; 336: 1776-1780 DOI: 10.1056/NEJM199706193362502. (PMID: 9187067)
• 13 Lambertini M, Del Mastro L, Bellodi A. et al. The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol 2014; 89: 112-128 DOI: 10.1016/j.critrevonc.2013.08.006. (PMID: 24041627)
• 14 Lapidari P, Vaz-Luis I, Di Meglio A. Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review. Crit Rev Oncol Hematol 2021; 157: 103193 DOI: 10.1016/j.critrevonc.2020.103193. (PMID: 33309891)
• 15 Lyman GH, Yau L, Nakov R. et al. Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. Annals of oncology: official journal of the European Society for Medical Oncology /ESMO 2018; 29: 1903-1910 DOI: 10.1093/annonc/mdy311.
• 16 Mahdi Seyedzadeh Sani S, Sahranavard M, Jannati Yazdanabad M. et al. The effect of concomitant use of Colony-Stimulating factors on bleomycin pulmonary toxicity – A systematic review and meta-analysis. Int Immunopharmacol 2022; 112: 109227 DOI: 10.1016/j.intimp.2022.109227.
• 17 Motzer RJ, Geller NL, Bosl GJ. The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patients. Cancer 1990; 66: 857-861 DOI: 10.1002/1097-0142(19900901)66:5<857::aid-cncr2820660508>3.0.co;2-g. (PMID: 1696846)
• 18 Mhaskar R, Clark OA, Lyman G. et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. The Cochrane database of systematic reviews 2014; 2014: CD003039 DOI: 10.1002/14651858.CD003039.pub2. (PMID: 25356786)
• 19 Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 2013; 21: 1487-1495 DOI: 10.1007/s00520-013-1758-y. (PMID: 23443617)
• 20 Cornes P, Gascon P, Gascon S. et al. Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia. Adv Ther 2018; 35: 1816-1829 DOI: 10.1007/s12325-018-0798-6.
• 21 Mitchell S, Li X, Woods M. et al. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review. J Oncol Pharm Pract 2016; 22: 702-716 DOI: 10.1177/1078155215625459.
• 22 Weycker D, Barron R, Edelsberg J. et al. Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis. BMC Health Serv Res 2014; 14: 189 DOI: 10.1186/1472-6963-14-189.
• 23 Lyman GH, Allcott K, Garcia J. et al. The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2017; 25: 2619-2629 DOI: 10.1007/s00520-017-3703-y.
• 24 Weycker D, Bensink M, Lonshteyn A. et al. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015. Curr Med Res Opin 2017; 33: 2107-2113 DOI: 10.1080/03007995.2017.1386858.
• 25 Aapro M, Boccia R, Leonard R. et al. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 2017; 25: 3295-3304 DOI: 10.1007/s00520-017-3842-1. (PMID: 28842778)